Cumberland Pharmaceuticals Stock Forecast, Price & News

-0.04 (-1.21 %)
(As of 07/23/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume18,361 shs
Average Volume27,296 shs
Market Capitalization$49.06 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CPIX News and Ratings via Email

Sign-up to receive the latest news and ratings for Cumberland Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Cumberland Pharmaceuticals logo

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its product include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, and RediTrex. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

0.77 out of 5 stars

Medical Sector

1301st out of 2,215 stocks

Pharmaceutical Preparations Industry

590th out of 867 stocks

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Cumberland Pharmaceuticals (NASDAQ:CPIX) Frequently Asked Questions

Is Cumberland Pharmaceuticals a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cumberland Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cumberland Pharmaceuticals stock.
View analyst ratings for Cumberland Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Cumberland Pharmaceuticals?

Wall Street analysts have given Cumberland Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cumberland Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Cumberland Pharmaceuticals' next earnings date?

Cumberland Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Cumberland Pharmaceuticals

How were Cumberland Pharmaceuticals' earnings last quarter?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released its earnings results on Monday, May, 10th. The specialty pharmaceutical company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.14. The specialty pharmaceutical company earned $10.54 million during the quarter, compared to analysts' expectations of $8.50 million. Cumberland Pharmaceuticals had a positive trailing twelve-month return on equity of 3.75% and a negative net margin of 5.34%.
View Cumberland Pharmaceuticals' earnings history

How has Cumberland Pharmaceuticals' stock been impacted by Coronavirus?

Cumberland Pharmaceuticals' stock was trading at $4.14 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CPIX stock has decreased by 21.3% and is now trading at $3.26.
View which stocks have been most impacted by COVID-19

Who are Cumberland Pharmaceuticals' key executives?

Cumberland Pharmaceuticals' management team includes the following people:
  • A. J. Kazimi, Chairman & Chief Executive Officer
  • Leo B. Pavliv, Chief Development Officer & EVP-Operations
  • John Hamm, Chief Financial & Accounting Officer
  • Martin E. Cearnal, Director, Chief Compliance Officer & Executive VP
  • James L. Herman, Chief Compliance Officer & Senior Vice President

What is A. J. Kazimi's approval rating as Cumberland Pharmaceuticals' CEO?

9 employees have rated Cumberland Pharmaceuticals CEO A. J. Kazimi on A. J. Kazimi has an approval rating of 9% among Cumberland Pharmaceuticals' employees. This puts A. J. Kazimi in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Cumberland Pharmaceuticals' key competitors?

What other stocks do shareholders of Cumberland Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cumberland Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), CymaBay Therapeutics (CBAY), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Akero Therapeutics (AKRO), Cerecor (CERC), CorMedix (CRMD) and Xeris Pharmaceuticals (XERS).

What is Cumberland Pharmaceuticals' stock symbol?

Cumberland Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPIX."

How do I buy shares of Cumberland Pharmaceuticals?

Shares of CPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cumberland Pharmaceuticals' stock price today?

One share of CPIX stock can currently be purchased for approximately $3.26.

How much money does Cumberland Pharmaceuticals make?

Cumberland Pharmaceuticals has a market capitalization of $49.06 million and generates $37.44 million in revenue each year. The specialty pharmaceutical company earns $-3,340,000.00 in net income (profit) each year or ($0.06) on an earnings per share basis.

How many employees does Cumberland Pharmaceuticals have?

Cumberland Pharmaceuticals employs 90 workers across the globe.

When was Cumberland Pharmaceuticals founded?

Cumberland Pharmaceuticals was founded in 1999.

What is Cumberland Pharmaceuticals' official website?

The official website for Cumberland Pharmaceuticals is

Where are Cumberland Pharmaceuticals' headquarters?

Cumberland Pharmaceuticals is headquartered at 2525 WEST END AVENUE SUITE 950, NASHVILLE TN, 37203.

How can I contact Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals' mailing address is 2525 WEST END AVENUE SUITE 950, NASHVILLE TN, 37203. The specialty pharmaceutical company can be reached via phone at (615) 255-0068 or via email at [email protected]

This page was last updated on 7/24/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.